CD49d is overexpressed by trisomy 12 chronic lymphocytic leukemia cells: evidence for a methylation-dependent regulation mechanism.

Zucchetto A, Caldana C, Benedetti D, Tissino E, Rossi FM, Hutterer E, Pozzo F, Bomben R, Dal Bo M, D’Arena G, Zaja F, Pozzato G, Di Raimondo F, Hartmann TN, Rossi D, Gaidano G, Del Poeta G, Gattei V. Blood. 2013 Nov 7,122(19):3317-21. doi: 10.1182/blood-2013-06-507335. Epub 2013 Sep 25.

Chemotherapy-induced augmentation of T cells expressing inhibitory receptors is reversed by treatment with lenalidomide in chronic lymphocytic leukemia.

Gassner FJ, Zaborsky N, Neureiter D, Huemer M, Melchardt T, Egle A, Rebhandl S, Catakovic K, Hartmann TN, Greil R, Geisberger R. Haematologica. 2014 May,99(5):67-9. doi: 10.3324/haematol.2013.098459. Epub 2014 Feb 21.

AID induces intraclonal diversity and genomic damage in CD86(+) chronic lymphocytic leukemia cells.

Huemer M, Rebhandl S, Zaborsky N, Gassner FJ, Hainzl S, Weiss L, Hebenstreit D, Greil R, Geisberger R. Eur J Immunol. 2014 Dec,44(12):3747-57. doi: 10.1002/eji.201344421. Epub 2014 Oct 18.

Alternative splice variants of AID are not stoichiometrically present at the protein level in chronic lymphocytic leukemia.

Rebhandl S, Huemer M, Zaborsky N, Gassner FJ, Catakovic K, Felder TK, Greil R, Geisberger R. Eur J Immunol. 2014 Jul,44(7):2175-87. doi: 10.1002/eji.201343853. Epub 2014 Apr 15.

APOBEC3 signature mutations in chronic lymphocytic leukemia.

Rebhandl S, Huemer M, Gassner FJ, Zaborsky N, Hebenstreit D, Catakovic K, Grössinger EM, Greil R, Geisberger R. Leukemia. 2014 Sep,28(9):1929-32. doi: 10.1038/leu.2014.160. Epub 2014 May 20.

Randomized phase II study of bortezomib, thalidomide and dexamethasone with or without cyclophosphamide as induction therapy in previously untreated multiple myeloma.

Ludwig H, Viterbo L, Greil R, Masszi T, Spicka I, Shpilberg O, Hajek R, Dmoszynska A, Paiva B, Vidriales MB, Esteves G, Stoppa AM, Robinson D Jr, Ricci D, Cakana A, Enny C, Feng H, van de Velde H, Harousseau JL. J Clin Oncol. 2013 Jan 10,31(2):247-55. doi: 10.1200/JCO.2011.39.5137. Epub 2012 Oct 22.

Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label non-inferiority phase 3 TURANDOT trial.

Lang I, Brodowicz T, Ryvo L, Kahan Z, Greil R, Beslija S, Stemmer SM, Kaufman B, Zvirbule Z, Steger GG, Melichar B, Pienkowski T, Sirbu D, Messinger D, Zielinski C Lancet Oncol. 2013 Feb,14(2):125-33. doi: 10.1016/S1470-2045(12)70566-1. Epub 2013 Jan 10.

Efficacy of tamoxifen ± aminoglutethimide in normal weight and overweight postmenopausal patients with hormone receptor-positive breast cancer: an analysis of 1509 patients of the ABCSG-06 trial.

Pfeiler G, Stöger H, Dubsky P, Mlineritsch B, Singer C, Balic M, Fitzal F, Moik M, Kwasny W, Selim U, Renner K, Ploner F, Steger GG, Seifert M, Hofbauer F, Sandbichler P, Samonigg H, Jakesz R, Greil R, Fesl C, Gnant M Br J Cancer. 2013 Apr 16,108(7):1408-14. doi: 10.1038/bjc.2013.114. Epub 2013 Mar 19.

Neoadjuvant chemotherapy and targeted therapy in breast cancer: past, present and future.

Gampenrieder SP, Rinnerthaler G, Greil R. J Oncol. 2013,2013:732047. doi: 10.1155/2013/732047. Epub 2013 Aug 20.

Topical evening primrose oil for reduction of bortezomib-induced skin reactions.

Auberger J, Vogt S, Hopfinger G, Clausen J, Greil R. Ann Hematol. 2013 Jul,92(7):995-6. doi: 10.1007/s00277-012-1656-2. Epub 2012 Dec 22.